首页IMM • ASX
add
Immutep Ltd
市场资讯
财务信息
损益表
收入
净收入
| (AUD) | 2023年12月info | 年同比变化 |
|---|---|---|
收入 | 105.54万 | 25.23% |
经营支出 | 240.11万 | 16.20% |
净收入 | -1061.41万 | -2.93% |
净利润率 | -1005.72 | 17.80% |
每股收益 | — | — |
息税折旧摊销前利润 | -1109.91万 | -8.28% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (AUD) | 2023年12月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 1.04亿 | 51.71% |
总资产 | 1.24亿 | 43.92% |
负债总额 | 814.60万 | -12.60% |
权益总额 | 1.16亿 | — |
发行在外的股份 | 11.89亿 | — |
市净率 | 4.65 | — |
资产回报率 | -23.35% | — |
资本回报率 | -24.65% | — |
现金流
现金净变动
| (AUD) | 2023年12月info | 年同比变化 |
|---|---|---|
净收入 | -1061.41万 | -2.93% |
来自运营的现金 | -922.52万 | -54.83% |
投资现金 | -20.96万 | -607.90% |
融资现金 | -21.59万 | -278.22% |
现金净变动 | -984.14万 | -69.40% |
自由现金流 | -689.61万 | -2.37% |
简介
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
CEO
成立时间
2001
员工数量
19
